Publications

Prostate Cancer after Initial High-Grade Prostatic Intraepithelial Neoplasia and Benign Prostate Biopsy

Can J Urol. 2015 Dec;22(6):8056-62.

Patel P, Nayak JG, Biljetina Z, Donnelly B, Trpkov K.

Abstract

INTRODUCTION:

Limited data exist on long term pathological outcomes in patients with initial prostate biopsies showing either high-grade intraepithelial neoplasia (HGPIN) or benign findings, who are subsequently diagnosed with prostate cancer.

MATERIALS AND METHODS:

Preoperative characteristics of patients showing either HGPIN or benign initial prostate biopsies were investigated and compared in patients with and without a subsequent diagnosis of prostate cancer. We also compared the biopsy and prostatectomy findings in patients with prostate cancer in both groups.

RESULTS:

We evaluated 161 and 85 patients with initial HGPIN and benign prostate biopsies, respectively, who underwent a subsequent biopsy. After a median follow up of 11 years, prostate cancer was detected in 26.7% patients after HGPIN and in 22.3% patients after initial benign biopsy. Ninety-eight percent of positive biopsies after initial HGPIN demonstrated either Gleason score (GS) 3 + 3 (86%) or GS 3 + 4 (12%). In the benign group, 100% of patients demonstrated prostate cancer on biopsy with either GS 3 + 3 (58%) or GS 3 + 4 (42%). Of 35 patients who underwent prostatectomy (22 after initial HGPIN biopsy and 13 after initial benign biopsy), all had node negative, organ-confined disease; 86% and 54% patients had GS6 disease, with = 5% tumor volume found in 91% and 62% of the HGPIN and benign group, respectively.

CONCLUSIONS:

Patients with initial HGPIN or benign biopsies preceding a diagnosis of prostate cancer usually show favourable pathology on positive biopsy and prostatectomy, most commonly exhibiting low volume and low grade disease. These findings may help clinicians risk-stratify patients who may benefit from conservative management options.

PubMed

APCaRI Fall Symposium Oct. 26 to 27, 2018, Banff, Alberta

2018 APCaRI Fall Symposium – Knowledge, Action, Impact

On October 26 – 27, 2018 APCaRI will celebrate its 11th research meeting at the Banff Park Lodge, in Banff, Alberta. Previous fall symposia have had over 60 participants participating in this fun and enriching event, including clinicians, scientists, clinical research personnel, trainees, benefactors and representatives of PCa support groups. Plan on attending the 2018 Fall symposium to discuss and share ideas and enjoy the beautiful Rockies!

Please submit your abstracts to Rume at djebah@ualberta.ca. Please let Rume know as soon as possible if you cannot attend. The APCaRI Fall symposium is generously supported by the Alberta Cancer Foundation and its’ donors

Dates to remember:

Trainee abstract submission deadline is September 10

Registration deadline is September 14

Submit abstracts to djebah@ualberta.ca.

APCaRI Fall symposium site- Banff Park Lodge
Banff Park Lodge

 

 

- Unknown